TY - JOUR
T1 - The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy
T2 - A randomized, sham-controlled clinical trial
AU - Argenta, Peter A.
AU - Ballman, Karla V.
AU - Geller, Melissa A.
AU - Carson, Linda F.
AU - Ghebre, Rahel
AU - Mullany, Sally A.
AU - Teoh, Deanna G.K.
AU - Winterhoff, Boris J.N.
AU - Rivard, Colleen L.
AU - Erickson, Britt K.
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer therapy with few efficacious treatments. Methods We enrolled 70 patients with CIPN in a randomized, double-blinded, sham-controlled, cross-over trial to determine if photobiomodulation (PBM) ± physiotherapy reduced the symptoms of neuropathy compared to sham treatment. At the conclusion of follow-up, sham-arm patients could cross-over into a third arm combining PBM and physiotherapy to determine if multimodal treatment had additive effects. Treatment included 30 minute sessions 3-times weekly for 6 weeks using either PBM or sham therapy. Neuropathy was assessed using the modified total neuropathy score (mTNS) at initiation and 4, 8, and 16 weeks after initiating treatment. Results Sham-treated patients experienced no significant change in mTNS scores at any point during the primary analysis. PBM patients experienced significant reduction in mTNS scores at all time points. Mean changes in mTNS score (and corresponding percent drop from baseline) for sham and PBM-group patients respectively were − 0.1 (− 0.7%) and − 4.2 (− 32.4%) at 4 weeks (p < 0.001), 0.2 (0.0%) and − 6.8 (− 52.6%) at 8 weeks (p < 0.001), and 0.0 (0.1%) and − 5.0 (− 38.8%) at 16 weeks (p < 0.001). Patients who crossed over into the PBM/PT-group experienced similar results to those treated primarily; changes in mTNS score from baseline were − 5.5 (− 40.6%) 4 weeks (p < 0.001), − 6.9 (− 50.9%) at 8 weeks (p < 0.001), and − 4.9 (− 35.9%) at 16 weeks (p < 0.001). The addition of physiotherapy did not improve outcomes over PBM alone. Conclusion and relevance Among patients with CIPN, PBM produced significant reduction in neuropathy symptoms.
AB - Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer therapy with few efficacious treatments. Methods We enrolled 70 patients with CIPN in a randomized, double-blinded, sham-controlled, cross-over trial to determine if photobiomodulation (PBM) ± physiotherapy reduced the symptoms of neuropathy compared to sham treatment. At the conclusion of follow-up, sham-arm patients could cross-over into a third arm combining PBM and physiotherapy to determine if multimodal treatment had additive effects. Treatment included 30 minute sessions 3-times weekly for 6 weeks using either PBM or sham therapy. Neuropathy was assessed using the modified total neuropathy score (mTNS) at initiation and 4, 8, and 16 weeks after initiating treatment. Results Sham-treated patients experienced no significant change in mTNS scores at any point during the primary analysis. PBM patients experienced significant reduction in mTNS scores at all time points. Mean changes in mTNS score (and corresponding percent drop from baseline) for sham and PBM-group patients respectively were − 0.1 (− 0.7%) and − 4.2 (− 32.4%) at 4 weeks (p < 0.001), 0.2 (0.0%) and − 6.8 (− 52.6%) at 8 weeks (p < 0.001), and 0.0 (0.1%) and − 5.0 (− 38.8%) at 16 weeks (p < 0.001). Patients who crossed over into the PBM/PT-group experienced similar results to those treated primarily; changes in mTNS score from baseline were − 5.5 (− 40.6%) 4 weeks (p < 0.001), − 6.9 (− 50.9%) at 8 weeks (p < 0.001), and − 4.9 (− 35.9%) at 16 weeks (p < 0.001). The addition of physiotherapy did not improve outcomes over PBM alone. Conclusion and relevance Among patients with CIPN, PBM produced significant reduction in neuropathy symptoms.
UR - http://www.scopus.com/inward/record.url?scp=85006830451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006830451&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2016.11.013
DO - 10.1016/j.ygyno.2016.11.013
M3 - Article
C2 - 27887804
AN - SCOPUS:85006830451
SN - 0090-8258
VL - 144
SP - 159
EP - 166
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -